FOLH1 and pachyonychia congenita: Currently, multiple clinical trials are ongoing to test the combination of effective treatments in CRPC for castration-sensitive PC, including ARATs, poly-ADP ribose polymerase inhibitors, CPIs, and lutetium 177-PSMA.